Helicobacter pylori and Related Gastrointestinal Diseases: Infection, Treatment, Prevention, and Beyond

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Medical Microbiology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 636

Special Issue Editor


E-Mail Website
Guest Editor
An Nan Hospital, China Medical University, Taichung, Taiwan
Interests: prevention and treatment of the peptic ulcer disease; gastric cancer; Helicobacter pylori (H. pylori) infection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Helicobacter pylori (H. pylori) is recognized as the primary causative agent of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma. This pathogen is implicated in a range of extra-gastrointestinal diseases. The global rise in antimicrobial resistance has led to a significant decrease in the effectiveness of standard triple therapy, now considered inadequate in many regions. Innovative approaches such as bismuth quadruple therapy, non-bismuth quadruple therapy (including sequential, concomitant, and hybrid therapies), high-dose dual therapy, vonoprazan triple therapy, and vonoprazan–tetracycline therapy have been developed to improve H. pylori eradication rates.

Despite these advances, the optimal first-line therapy offering the highest eradication rate with minimal side effects remains elusive. Additionally, the potential of vaccines to prevent the transmission of H. pylori is still not fully understood, continuing to present a significant challenge to gastroenterologists 40 years post discovery.

We invite investigators to submit original research and review articles that explore recent advances in understanding the pathogenesis of H. pylori, evaluate promising first-line and rescue therapies, and discuss strategies for vaccination against H. pylori infection. Potential topics may include, but are not limited to, the following:

  • The epidemiology of H. pylori infection and its public health implications.
  • Molecular interactions between H. pylori and the human gastric mucosa.
  • Extra-gastrointestinal manifestations of H. pylori infection.
  • Advances in diagnosing H. pylori infection.
  • Emerging first-line and second-line therapies against H. pylori.
  • Current and future strategies for preventing gastric cancer beyond H. pylori infection.

The development and implications of vaccinating against H. pylori.

Dr. Ping I. Hsu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Helicobacter pylori (H. pylori)
  • gastrointestinal diseases
  • infection
  • treatment
  • prevention
  • vaccination
  • pathogenesis
 

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

14 pages, 777 KiB  
Systematic Review
Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review
by Chih-An Shih, Deng-Chyang Wu, Chang-Bih Shie and Ping-I Hsu
Microorganisms 2025, 13(4), 715; https://doi.org/10.3390/microorganisms13040715 - 21 Mar 2025
Viewed by 522
Abstract
Due to the increasing prevalence of antimicrobial resistance, the efficacy of standard triple therapy for Helicobacter pylori (H. pylori) infection has declined, with eradication rates now falling below 80% in most countries. Although bismuth quadruple therapy and concomitant therapy are advised [...] Read more.
Due to the increasing prevalence of antimicrobial resistance, the efficacy of standard triple therapy for Helicobacter pylori (H. pylori) infection has declined, with eradication rates now falling below 80% in most countries. Although bismuth quadruple therapy and concomitant therapy are advised in regions with high clarithromycin resistance, these treatments commonly cause frequent adverse events and require the use of two or three antibiotics. This review article evaluates the effectiveness of 14-day mono-antibiotic therapies for H. pylori infection through randomized controlled trials conducted from 1 October 2014 to 1 October 2024. The pooled eradication rates for 14-day high-dose amoxicillin/proton pump inhibitor (PPI) dual therapies were 86.1% (3335/3875; 95% confidence interval (CI): 85.1–87.2%) by intention-to-treat (ITT) analysis and 87.3% (3232/3702; 95% CI: 86.2–88.4%) by per-protocol (PP) analysis. For 14-day high-dose amoxicillin/vonoprazan dual therapies, the rates were 87.4% (1085/1241; 95% CI: 85.5–89.2%) by ITT and 93.0% (1044/1124; 95% CI: 91.5–94.5%) by PP. In the penicillin-allergic population, 14-day tetracycline/vonoprazan dual therapy showed eradication rates of 92.0% (138/150) by ITT and 95.1% (135/142) by PP. In conclusion, 14-day tetracycline/vonoprazan dual therapy presents an effective option for eradicating H. pylori in patients allergic to penicillin. For those without a penicillin allergy, first-line treatments can include 14-day mono-antibiotic regimens, such as high-dose amoxicillin/PPI dual, high-dose amoxicillin/vonoprazan dual, and tetracycline/vonoprazan dual therapies. Full article
Show Figures

Figure 1

Back to TopTop